{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T11:22:08Z","timestamp":1763810528953,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s12020-021-02782-2","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T05:09:02Z","timestamp":1622696942000},"page":"396-403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Long-term safety and efficacy of long-acting pasireotide in acromegaly"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9376-344X","authenticated-orcid":false,"given":"Amit","family":"Akirov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Gorshtein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idit","family":"Dotan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nariman Saba","family":"Khazen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulia","family":"Pauker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Gershinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilan","family":"Shimon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"issue":"7","key":"2782_CR1","first-page":"411","volume":"110","author":"R Dineen","year":"2017","unstructured":"R. Dineen, P.M. Stewart, M. Sherlock, Acromegaly. QJM 110(7), 411\u2013420 (2017)","journal-title":"QJM"},{"issue":"Dec","key":"2782_CR2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"4","author":"A Giustina","year":"2020","unstructured":"A. Giustina, G. Barkhoudarian, A. Beckers, A. Ben-shlomo, N. Biermasz, B. Biller, Multidisciplinary management of acromegaly: a consensus. Rev. Endocr. Metab. Disord. 4(Dec), 667\u2013678 (2020)","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"11","key":"2782_CR3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"M.R. Gadelha, M.D. Bronstein, T. Brue, M. Coculescu, M. Fleseriu, M. Guitelman, V. Pronin, G. Raverot, I. Shimon, K.K. Lievre, J. Fleck, M. Aout, A.M. Pedroncelli, A. Colao, Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2(11), 875\u2013884 (2014)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"2782_CR4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"A. Colao, M.D. Bronstein, P. Freda, F. Gu, C.C. Shen, M. Gadelha, M. Fleseriu, A.J. Van Der Lely, A.J. Farrall, K. Hermosillo Res\u00e9ndiz, M. Ruffin, Y. Chen, M. Sheppard, Pasireotide versus octreotide in acromegaly: A head-to-head superiority study. J. Clin. Endocrinol. Metab. 99(3), 791\u2013799 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"2782_CR5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/EJE-19-0762","volume":"182","author":"A Colao","year":"2020","unstructured":"A. Colao, M.D. Bronstein, T. Brue, L. De Marinis, M. Fleseriu, M. Guitelman, G. Raverot, I. Shimon, J. Fleck, P. Gupta, A.M. Pedroncelli, M.R. Gadelha, Pasireotide for acromegaly: Long-term outcomes from an extension to the phase III PAOLA study. Eur. J. Endocrinol. 182(6), 583\u2013594 (2020)","journal-title":"Eur. J. Endocrinol."},{"issue":"Feb","key":"2782_CR6","first-page":"1","volume":"10","author":"M Gadelha","year":"2020","unstructured":"M. Gadelha, M. Bex, A. Colao, E.M. Pedroza Garc\u00eda, C. Poiana, M. Jimenez-Sanchez, S. Yener, R. Mukherjee, A. Bartalotta, R. Maamari, G. Raverot, Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs. Front. Endocrinol. 10(Feb), 1\u201310 (2020)","journal-title":"Front. Endocrinol."},{"issue":"2","key":"2782_CR7","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1530\/EJE-19-0124","volume":"181","author":"J Bollerslev","year":"2019","unstructured":"J. Bollerslev, A. Heck, N.C. Olarescu, Individualised management of acromegaly. Eur. J. Endocrinol. 181(2), R57\u2013R71. (2019)","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"2782_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"M. Fleseriu, B.M.K. Biller, P.U. Freda, M.R. Gadelha, A. Giustina, L. Katznelson, M.E. Molitch, S.L. Samson, C.J. Strasburger, A.J. van der Lely, S. Melmed, A Pituitary Society update to acromegaly management guidelines. Pituitary 24(1), 1\u201313 (2021)","journal-title":"Pituitary"},{"issue":"6","key":"2782_CR9","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1210\/jc.2018-01979","volume":"104","author":"EC Coopmans","year":"2019","unstructured":"E.C. Coopmans, A. Muhammad, A.J. Van Der Lely, J.A.M.J.L. Janssen, S.J.C.M.M. Neggers, How to position pasireotide LAR treatment in acromegaly. J. Clin. Endocrinol. Metab. 104(6), 1978\u20131988 (2019)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"2782_CR10","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1210\/jc.2017-02017","volume":"103","author":"A Muhammad","year":"2018","unstructured":"A. Muhammad, A.J. Van Der Lely, P.J.D. Delhanty, A.H.G. Dallenga, I.K. Haitsma, J.A.M.J.L. Janssen, S.J.C.M.M. Neggers, Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE Study). J. Clin. Endocrinol. Metab. 103(2), 586\u2013595 (2018)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"2782_CR11","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s12020-018-1690-5","volume":"62","author":"I Shimon","year":"2018","unstructured":"I. Shimon, Z. Adnan, A. Gorshtein, L. Baraf, N. Saba Khazen, M. Gershinsky, Y. Pauker, A. Abid, M.J. Niven, C. Shechner, Y. Greenman, Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine 62(2), 448\u2013455 (2018)","journal-title":"Endocrine"},{"issue":"6","key":"2782_CR12","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1210\/me.2010-0398","volume":"25","author":"YJ Kao","year":"2011","unstructured":"Y.J. Kao, M. Ghosh, A. Schonbrunn, Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists. Mol. Endocrinol. 25(6), 1040\u20131054 (2011)","journal-title":"Mol. Endocrinol."},{"issue":"20","key":"2782_CR13","doi-asserted-by":"publisher","first-page":"21374","DOI":"10.1074\/jbc.M313522200","volume":"279","author":"G Tulipano","year":"2004","unstructured":"G. Tulipano, R. Stumm, M. Pfeiffer, V. Ho, S. Schulz, Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J. Biol. Chem. 279(20), 21374\u201321382 (2004)","journal-title":"J. Biol. Chem."},{"issue":"1","key":"2782_CR14","first-page":"84","volume":"16","author":"I Shimon","year":"2017","unstructured":"I. Shimon, W. Saeger, L.E. Wildemberg, M.R. Gadelha, Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control. Hormones 16(1), 84\u201391 (2017)","journal-title":"Hormones"},{"issue":"12","key":"2782_CR15","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1530\/EC-20-0361","volume":"9","author":"MR Gadelha","year":"2020","unstructured":"M.R. Gadelha, F. Gu, M.D. Bronstein, T.C. Brue, M. Fleseriu, I. Shimon, A.J. van der Lely, S. Ravichandran, A. Kandra, A.M. Pedroncelli, A.A.L. Colao, Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocr. Connect 9(12), 1178\u20131190 (2020)","journal-title":"Endocr. Connect"},{"issue":"1","key":"2782_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s12020-016-0895-8","volume":"53","author":"HA Schmid","year":"2016","unstructured":"H.A. Schmid, T. Brue, A. Colao, M.R. Gadelha, I. Shimon, K. Kapur, A.M. Pedroncelli, M. Fleseriu, Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine 53(1), 210\u2013219 (2016)","journal-title":"Endocrine"},{"issue":"5","key":"2782_CR17","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s11102-020-01055-x","volume":"23","author":"M Barbot","year":"2020","unstructured":"M. Barbot, D. Regazzo, A. Mondin, M. Zilio, L. Lizzul, M. Zaninotto, M. Plebani, G. Arnaldi, F. Ceccato, C. Scaroni, Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis. Pituitary 23(5), 534\u2013542 (2020)","journal-title":"Pituitary"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02782-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-021-02782-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02782-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T06:54:03Z","timestamp":1633676043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-021-02782-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["2782"],"URL":"https:\/\/doi.org\/10.1007\/s12020-021-02782-2","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"type":"print","value":"1355-008X"},{"type":"electronic","value":"1559-0100"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"assertion":[{"value":"23 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}